Mitsui Chemicals signs $11.6B deal to buy chip materials maker JSR from JIC
What's the deal? Mitsui ChemicalsDealroom has a profile for this one. Try Dealroom → signed a share purchase agreement on 9 November 2026 to buy semiconductor materials maker JSRDealroom has a profile for this one. Try Dealroom → from funds managed by JIC CapitalDealroom has a profile for this one. Try Dealroom →, the private equity arm of state-backed Japan Investment Corp. The Development Bank of JapanDealroom has a profile for this one. Try Dealroom → is co-investing US$1.54B through non-voting preferred shares, so Mitsui will hold all voting rights. JSR and four affiliates, including EUV photoresist developer Inpria and contract drug manufacturer KBI Biopharma, will become Mitsui subsidiaries.
The price: Mitsui puts the acquisition price at US$14.2B, made up of US$10.7B of equity value and US$3.45B of debt and other items, subject to closing adjustments. Mitsui says that is about 16 times JSR's expected EBITDA for the current fiscal year. It is more than double Showa Denko's 2020 purchase of Hitachi Chemical (now ResonacDealroom has a profile for this one. Try Dealroom →), until now the benchmark deal in Japanese chip materials, and roughly twice the US$6.92B JIC paid to take JSR private in 2024.
Why it matters: JSR is one of the world's largest makers of photoresists, the light-sensitive chemicals used to print circuit patterns onto wafers, and second only to Tokyo Ohka KogyoDealroom has a profile for this one. Try Dealroom →. Mitsui already leads in pellicles, the films that protect photomasks, and makes chip-packaging tapes and resists. JSR becomes the core of Mitsui's ICT solutions business, and Mitsui calls the deal a step toward becoming a global specialty chemicals company, with a target of US$2.31B or more in core operating profit by fiscal 2030.
How it is paid for: Mitsui is taking a US$12.6B bridge loan and filed a shelf registration to sell up to about US$1.15B of new shares, with bonds, loans and mezzanine financing to follow. Its market value is well below the purchase price, so it plans to sell JSR's life sciences unit and other non-core businesses and aims to cut leverage within three years while keeping an A-range credit rating. Mitsui is also widening the scope of a planned split-off of its basic and green materials business.
What's next? The deal needs competition and foreign-investment approvals in Japan and abroad. Mitsui is targeting completion in the second half of the fiscal year ending March 2028. For JIC, the sale delivers on its plan to use JSR as a vehicle for consolidating Japan's semiconductor materials sector.
Sources: Mitsui Chemicals disclosure (9 Nov 2026), Reuters via CNA, TechNode Global
Image credit: IBM Research